May 07, 2021 4:01 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
May 04, 2021 4:01 pm EDT Atara Biotherapeutics Announces First Quarter 2021 Financial Results and Operational Progress
Apr 27, 2021 5:51 pm EDT Atara Biotherapeutics to Announce First Quarter 2021 Financial Results on Tuesday, May 4, 2021
Apr 02, 2021 4:35 pm EDT Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Mar 14, 2021 4:00 pm EDT Atara Biotherapeutics Presents New Long-Term Overall Survival Data from a Combined Analysis of Phase 2 Tab-cel® Studies for Epstein-Barr Virus-Driven Post-Transplant Lymphoproliferative Disease at The EBMT 2021 Annual Meeting
Mar 05, 2021 4:01 pm EST Atara Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Mar 01, 2021 4:05 pm EST Atara Biotherapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Operational Progress
Feb 18, 2021 4:01 pm EST Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2020 Financial Results on Monday, March 1, 2021
Feb 08, 2021 9:00 am EST Atara Biotherapeutics Presents Key Data for Advancing the Development of Tab-cel® and ATA188 at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience